Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2007 1
2010 1
2012 2
2013 1
2014 2
2016 2
2018 2
2019 2
2020 4
2021 2
2022 3
2023 4
2024 4
2025 8

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

34 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean m mortaz (12 results)?
Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer.
Rojas LA, Sethna Z, Soares KC, Olcese C, Pang N, Patterson E, Lihm J, Ceglia N, Guasp P, Chu A, Yu R, Chandra AK, Waters T, Ruan J, Amisaki M, Zebboudj A, Odgerel Z, Payne G, Derhovanessian E, Müller F, Rhee I, Yadav M, Dobrin A, Sadelain M, Łuksza M, Cohen N, Tang L, Basturk O, Gönen M, Katz S, Do RK, Epstein AS, Momtaz P, Park W, Sugarman R, Varghese AM, Won E, Desai A, Wei AC, D'Angelica MI, Kingham TP, Mellman I, Merghoub T, Wolchok JD, Sahin U, Türeci Ö, Greenbaum BD, Jarnagin WR, Drebin J, O'Reilly EM, Balachandran VP. Rojas LA, et al. Nature. 2023 Jun;618(7963):144-150. doi: 10.1038/s41586-023-06063-y. Epub 2023 May 10. Nature. 2023. PMID: 37165196 Free PMC article. Clinical Trial.
RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer.
Sethna Z, Guasp P, Reiche C, Milighetti M, Ceglia N, Patterson E, Lihm J, Payne G, Lyudovyk O, Rojas LA, Pang N, Ohmoto A, Amisaki M, Zebboudj A, Odgerel Z, Bruno EM, Zhang SL, Cheng C, Elhanati Y, Derhovanessian E, Manning L, Müller F, Rhee I, Yadav M, Merghoub T, Wolchok JD, Basturk O, Gönen M, Epstein AS, Momtaz P, Park W, Sugarman R, Varghese AM, Won E, Desai A, Wei AC, D'Angelica MI, Kingham TP, Soares KC, Jarnagin WR, Drebin J, O'Reilly EM, Mellman I, Sahin U, Türeci Ö, Greenbaum BD, Balachandran VP. Sethna Z, et al. Nature. 2025 Mar;639(8056):1042-1051. doi: 10.1038/s41586-024-08508-4. Epub 2025 Feb 19. Nature. 2025. PMID: 39972124 Free PMC article. Clinical Trial.
At an extended 3.2-year median follow-up from a phase 1 trial of surgery, atezolizumab (PD-L1 inhibitory antibody), autogene cevumeran(1) (individualized neoantigen vaccine with backbone-optimized uridine mRNA-lipoplex nanoparticles) and modified (m) FOLFIRINOX (chemothera …
At an extended 3.2-year median follow-up from a phase 1 trial of surgery, atezolizumab (PD-L1 inhibitory antibody), autogene cevumeran(1) (i …
Neoadjuvant relatlimab and nivolumab in resectable melanoma.
Amaria RN, Postow M, Burton EM, Tetzlaff MT, Ross MI, Torres-Cabala C, Glitza IC, Duan F, Milton DR, Busam K, Simpson L, McQuade JL, Wong MK, Gershenwald JE, Lee JE, Goepfert RP, Keung EZ, Fisher SB, Betof-Warner A, Shoushtari AN, Callahan M, Coit D, Bartlett EK, Bello D, Momtaz P, Nicholas C, Gu A, Zhang X, Korivi BR, Patnana M, Patel SP, Diab A, Lucci A, Prieto VG, Davies MA, Allison JP, Sharma P, Wargo JA, Ariyan C, Tawbi HA. Amaria RN, et al. Nature. 2022 Nov;611(7934):155-160. doi: 10.1038/s41586-022-05368-8. Epub 2022 Oct 26. Nature. 2022. PMID: 36289334 Free PMC article. Clinical Trial.
First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial.
Janjigian YY, Maron SB, Chatila WK, Millang B, Chavan SS, Alterman C, Chou JF, Segal MF, Simmons MZ, Momtaz P, Shcherba M, Ku GY, Zervoudakis A, Won ES, Kelsen DP, Ilson DH, Nagy RJ, Lanman RB, Ptashkin RN, Donoghue MTA, Capanu M, Taylor BS, Solit DB, Schultz N, Hechtman JF. Janjigian YY, et al. Lancet Oncol. 2020 Jun;21(6):821-831. doi: 10.1016/S1470-2045(20)30169-8. Epub 2020 May 18. Lancet Oncol. 2020. PMID: 32437664 Free PMC article. Clinical Trial.
For subsequent cycles, patients received 130 mg/m(2) of intravenous oxaliplatin or 80 mg/m(2) of cisplatin on day 1, 850 mg/m(2) of oral capecitabine twice a day for 2 weeks followed by 1 week off (or intravenous 5-fluorouracil, 800 mg/m(2) per day on …
For subsequent cycles, patients received 130 mg/m(2) of intravenous oxaliplatin or 80 mg/m(2) of cisplatin on day 1, 850 mg/ …
Retraction Statement: Novel NAD-independent Avibacterium paragallinarum: Isolation, characterization and molecular identification in Iran.
[No authors listed] [No authors listed] Vet Med Sci. 2023 Sep;9(5):2390. doi: 10.1002/vms3.1257. Epub 2023 Sep 15. Vet Med Sci. 2023. PMID: 37713440 Free PMC article.
Beiranvand, S., Piri-Gharaghie, T., Dehganzad, B., Khedmati, F., Jalali, F., AsadAlizadeh, M., & Momtaz, H. (2022). Novel NAD-independent Avibacterium paragallinarum: Isolation, characterization and molecular identification in Iran. ...
Beiranvand, S., Piri-Gharaghie, T., Dehganzad, B., Khedmati, F., Jalali, F., AsadAlizadeh, M., & Momtaz, H. (2022). Novel …
Early On-Treatment Assessment of T Cells, Cytokines, and Tumor DNA with Adaptively Dosed Nivolumab + Ipilimumab: Final Results from the Phase 2 ADAPT-IT Study.
Smithy JW, Kalvin HL, Ehrich FD, Shah R, Adamow M, Raber V, Maher CA, Kleman J, McIntyre DAG, Shoushtari AN, Betof Warner A, Callahan MK, Momtaz P, Eton O, Nair S, Wolchok JD, Chapman PB, Berger MF, Panageas KS, Postow MA. Smithy JW, et al. Clin Cancer Res. 2024 Aug 15;30(16):3407-3415. doi: 10.1158/1078-0432.CCR-23-3643. Clin Cancer Res. 2024. PMID: 38767650 Free PMC article. Clinical Trial.
Programmed death ligand-1 PET imaging in patients with melanoma: a pilot study.
Pandit-Taskar N, Mauguen A, Frosina D, Jungbluth A, Busam KJ, Lyashchenko S, Schwartz J, Momtaz P, Warner AB, Smithy JW, Shoushtari AN, Callahan MK, Chapman PB, Postow MA. Pandit-Taskar N, et al. Melanoma Res. 2025 Oct 1;35(5):328-338. doi: 10.1097/CMR.0000000000001050. Epub 2025 Jun 25. Melanoma Res. 2025. PMID: 40557547 Free PMC article.
Helodermin-loaded nanoparticles: characterization and transport across an in vitro model of the follicle-associated epithelium.
des Rieux A, Fievez V, Momtaz M, Detrembleur C, Alonso-Sande M, Van Gelder J, Cauvin A, Schneider YJ, Préat V. des Rieux A, et al. J Control Release. 2007 Apr 23;118(3):294-302. doi: 10.1016/j.jconrel.2006.12.023. Epub 2006 Dec 29. J Control Release. 2007. PMID: 17292503
M cells represent a potential portal for oral delivery of peptides and proteins due to their high endocytosis abilities. ...M cells enhanced transport of intact helodermin (18-fold, Papp=3 x 10(-6) cm s(-1)). ...
M cells represent a potential portal for oral delivery of peptides and proteins due to their high endocytosis abilities. ...M …
Occupational exposure to particulate matters and telomere length.
Sanei B, Zavar Reza J, Momtaz M, Azimi M, Zare Sakhvidi MJ. Sanei B, et al. Environ Sci Pollut Res Int. 2018 Dec;25(36):36298-36305. doi: 10.1007/s11356-018-3486-9. Epub 2018 Oct 27. Environ Sci Pollut Res Int. 2018. PMID: 30368702
Exposure to inhalable and respirable dusts in the exposed group was 22.66 52.38 and 2.54 9.34 mg/m(3) respectively. Inhalable and respirable exposure values were highly correlated (r(2) = 0.43; p < 0.001). ...
Exposure to inhalable and respirable dusts in the exposed group was 22.66 52.38 and 2.54 9.34 mg/m(3) respectively. Inhalable and res …
34 results